Synopsis: Dr. Reddy’s Laboratories has reported a temporary delay in commercial supplies of its generic semaglutide due to an API quality issue, while manufacturing partner OneSource Specialty Pharma clarified that the development will not have any material financial or operational impact on its business.

The global market for GLP-1 therapies has emerged as one of the fastest-growing segments in the pharmaceutical industry, driven by the rising prevalence of diabetes and obesity. As demand for semaglutide-based medicines accelerates worldwide, pharmaceutical companies are racing to establish manufacturing capacity while maintaining stringent quality standards and uninterrupted supply chains.

Shares of Dr. Reddy’s Laboratories were trading at Rs. 1,275, down 5.49 percent during Thursday’s session. The stock moved within a 52-week range of Rs. 1,148.40 to Rs. 1,414.90, taking the company’s market capitalisation to approximately Rs. 1.06 lakh crore. Meanwhile, OneSource Specialty Pharma was trading at Rs. 1,637.20, up 1.56 percent, with a market capitalisation of around Rs. 18,769 crore, though the stock remained nearly 19 percent lower than its level a year ago.

What’s the News?

Dr. Reddy’s Laboratories has informed the stock exchanges that certain batches of its generic semaglutide product were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in manufacturing. The company has initiated a detailed investigation to identify the root cause.

As a result of the quality issue, Dr. Reddy’s said commercial supplies of semaglutide will be delayed for a certain period until corrective actions are completed. However, the company clarified that the issue does not impact patient safety and has no effect on its existing global regulatory filings.

To provide further clarity, Dr. Reddy’s scheduled an investor conference call on the same day to discuss the issue and answer shareholder queries. The company also stated that both the audio recording and transcript of the discussion would be made available on its website.

In its exchange filing, the company reiterated its commitment to maintaining product quality and ensuring reliable supplies of metabolic therapies. Management stated that it is actively investigating the issue while implementing appropriate corrective measures before resuming commercial distribution.

Shortly after Dr. Reddy’s announcement, OneSource Specialty Pharma, which serves as the manufacturing partner for Dr. Reddy’s generic semaglutide injection, issued a separate clarification addressing investor concerns arising from the temporary supply disruption.

OneSource stated that the delay disclosed by Dr. Reddy’s does not have any material financial or operational impact on its own business. The company emphasized that its manufacturing capacities remain fully committed through demand from multiple customers across different geographies.

The company further highlighted that it continues to receive strong demand from customers, including those in Canada, and reaffirmed its long-term partnership with Dr. Reddy’s. According to the company, ongoing capacity additions will enable it to meet future requirements once commercial supplies resume.

OneSource also noted that significant manufacturing capacity expansion is scheduled to commence during the current quarter and later this year, in line with previously announced growth plans aimed at supporting increasing demand for complex injectable and biologic products.

Financial & Business Analysis

For Dr. Reddy’s, the delay appears to be an operational timing issue rather than a structural setback. The company confirmed that the issue is limited to certain semaglutide batches and does not affect patient safety or regulatory approvals, preserving the long-term commercial opportunity in one of the world’s fastest-growing diabetes and obesity therapy markets.

While the postponement could delay revenue recognition from semaglutide, Dr. Reddy’s remains financially resilient. In FY26, the company reported revenue of Rs. 33,700 crore and net profit of Rs. 4,158 crore. Its diversified portfolio spanning APIs, generics, biosimilars, branded formulations, and custom pharmaceutical services reduces dependence on any single product, enabling it to absorb temporary manufacturing disruptions without materially affecting overall business stability.

The clarification also eased concerns surrounding OneSource Specialty Pharma, Dr. Reddy’s manufacturing partner. The company stated that the delayed supplies are not expected to materially impact its earnings, reflecting its diversified CDMO customer base rather than reliance on a single commercial programme.

OneSource continues to strengthen its long-term growth platform through capacity expansion across biologics and injectable manufacturing. The company recently completed a USFDA inspection of its Bengaluru sterile products facility with only one observation, supporting its strategy to scale operations and deepen relationships with global biopharma clients.

The clarification from OneSource Specialty Pharma successfully eased immediate panic regarding its operational stability. Financially, OneSource is navigating a heavy investment phase; while its March 2026 quarterly revenue came in strong at Rs. 428.22 crore marking a sharp 47.5% growth sequentially over the previous quarter, its quarterly net profit dropped to Rs. 4.60 crore. This temporary compression reflects rising manufacturing expenses (which climbed to Rs. 336.31 crore) and capacity expansion costs.

For the full year FY26, OneSource recorded robust top-line traction with sales hitting Rs. 1,422 crore, supported by an impressive three-year sales compound annual growth rate (CAGR) of 232%. However, bottom-line profitability remains under near-term pressure due to the company’s aggressive capacity scaling, resulting in a full-year net loss of Rs. 74 crore. 

Despite these transient margin pressures, OneSource’s diversified contract development and manufacturing (CDMO) client base ensures it does not depend on a single commercial pipeline, while its massive Rs. 5,820 crore reserve base provides a substantial capital buffer as it commercializes new facilities.

Industry & Strategic Analysis

Semaglutide has emerged as one of the pharmaceutical industry’s biggest growth opportunities, driven by rising demand for GLP-1 therapies for diabetes and obesity. Upcoming patent expiries are expected to create significant opportunities for generic drugmakers with strong manufacturing quality and regulatory compliance.

The temporary API-related issue highlights the importance of robust pharmaceutical supply chains, where even minor quality deviations can delay commercial launches. For OneSource, its diversified CDMO business, expanding manufacturing footprint, and multiple global partnerships reduce customer concentration risk and support long-term growth.

Investors will closely watch Dr. Reddy’s progress in resolving the manufacturing issue and resuming semaglutide supplies. On the otherhand, OneSource’s ability to execute capacity expansion and convert its growing global partnership pipeline into commercial revenues remains a key long-term monitorable.

Company Overview

Dr. Reddy’s Laboratories Limited is a Hyderabad-based global pharmaceutical company engaged in active pharmaceutical ingredients, generic medicines, biosimilars and differentiated formulations across India, the United States, Europe, Russia and several emerging markets.

OneSource Specialty Pharma Limited is a Bengaluru-based contract development and manufacturing organisation specializing in biologics, biosimilars, sterile injectables, vaccines and other complex pharmaceutical products. The company operates globally compliant manufacturing facilities and serves pharmaceutical companies across multiple international markets.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Dr. Reddy’s Delays Generic Semaglutide Supplies; Partner OneSource Sees No Impact appeared first on Trade Brains.